Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
- Doctors Without Borders contests Pfizer’s patent on pneumonia vaccine
- Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules
- The Trans-Pacific Partnership is back: experts respond
- THERE IS ONLY ONE SURE WAY TO FIX THE HEPATITIS C EPIDEMIC
- Time for costly medicine monopolies to go from TPP trade talks